Background: Thymoglobulin has been used for induction therapy to prevent acute rejection and delayed graft function (DGF) in kidney transplant patients. However, the usual dose of thymoglobulin is considered to be related with frequent infection. We compared the efficacy and safety of low-dose thymoglobulin to high-dose treatment in high risk recipients with kidney transplantation.
INTRODUCTION
Thymoglobulin is one of the most widely used induction immunosuppressant in kidney transplantation. It was better than basiliximab on acute rejection and graft survival rate by 5 and 10 years follow-up (1, 2) . Kidney transplantation is the best treatment for chronic kidney disease, and it has been performed increasingly in patients with high risk for acute antibody-mediated rejection (AMR) and delayed graft function (DGF). Brennan et al.(3) presented that thymoglobulin is better than basiliximab for high risk patients, reduced acute rejection rate and severity (3) (4) (5) . However the usual dose of thymoglobulin (7∼10 mg/kg) may contribute to increase risk of infectious disease or malignancy (6) . Even low-dose thymoglobulin reduced risk for acute rejections and maintained better kidney function by 3 and 5 years fol- low-up than basiliximab (7) . There are some studies to find out efficacy and safety of low-dose thymoglobulin, but there is no consensus for optimal dose, especially for high risk patients yet (7, 8) . In this study, we suggest the optimal dose of thymoglobulin for high risk patients to prevent acute rejection or DGF include patients who transplanted from extended criteria donor.
MATERIALS AND METHODS
The report is retrospective study of kidney transplantation 
RESULTS
The baseline demography was similar between two groups.
There were no statistical differences between two groups in the number of both recipient's and donor's age over 60 years, and the number of deceased donor. The rate of HLA full mismatch was higher in group B than group A, but there was no statistical significance. Both groups were similar in the number of patients with PRA ＞50%, DSA (+).
Re-transplantation rates were similar between two groups; there was one case of third transplantation in group A. The Group A presented lower incidence of DGF and higher in the incidence of AMR than group B, but there were no significant differences. There were no differences in CMV infection and urinary tract infection. There were eight cases of CMV gastritis (4 vs. 4), one CMV nephritis (group B).
There were three patients who had presented CMV infection twice or more (1 vs. 2). In group A, there was one miliary tuberculosis. In addition, there was one pulmonary tuberculosis with central nervous system tuberculoma in group B. One BK virus infection was presented as BK viremia with BK nephropathy that occurred in group A. There was no statistical difference in overall infectious disease between two groups. Lymphocele was occurred only one case which is group B. Hematologic complications including neutropenia and thrombocytopenia occurred similarly between two groups. The serious adverse events such as serum sickness and delayed cardiopulmonary reaction did not occur in both groups. There was one case of graft loss in group B (Table 2 ). The cause of graft loss was uncontrolled rejection combined with infection.
DISCUSSION
Among patients with high risk for acute AMR and DGF, thymoglobulin is better than basiliximab in diverse aspects(1-5). But basiliximab is preferred to thymoglobulin because full dose thymoglobulin (7∼10 mg/kg) was associated with higher rates of infectious disease or hematologic complications. In most cases, infection rates were high in full dose thymoglobulin group, so we designed cut off level of thymoglobulin by 6 mg/kg and compared acute AMR, DGF, infection, hematologic complication, and graft survival between two groups(6).
There were no statistical differences in acute AMR and DGF between two groups. Acute rejections were more frequent in low-dose thymoglobulin group because there were more patients with high PRA or re-transplantation in group A. DGF were more frequent in group B because there were more cases with extended criteria donors.
Use of thymoglobulin more than 7 mg/kg has been associated with more frequent infectious complications (6) .
Although divided by 6 mg/kg, there were no significant differences between two groups in this study. CMV infections occurred more frequently in our study irrespective of thymoglobulin dose, compared to usual incidence. Especially, recurrent CMV infections were more frequent in high-dose thymoglobulin group. It seems to need more intensive prophylaxis to prevent CMV infection in the patient treated with thymoglobulin by induction therapy(9).
By using low-dose thymoglobulin, we could not observe differences in acute rejection and graft loss compare to high-dose thymoglobulin. It suggests that low-dose thymoglobulin is not inferior to high-dose on the effect of defending an acute rejection and DGF. We recommend the optimal dose of thymoglobulin to be less than 6 mg/kg.
We recognized that our study has several limitations. The result was seems to be carried out with relatively small number of patients, which limits its statistical power to compare the effect of low-dose thymoglobulin with high-dose thymoglobulin in high risk patients. In addition, the period for following up the patients' course were not sufficient. It would be innovative to identify the optimal dose of thymoglobulin if the large study is performed with long term follow-up.
CONCLUSION
Low dose thymoglobulin was effective as much as high dose for prevention of acute rejection and DGF in high risk patients. The incidences of complications like infection and hematologic problem were not different between two groups. Although we need more study to lower the dose of thymoglobulin, we can suggest that less than 6 mg/kg of thymoglobulin is efficient for prevention of acute rejection and DGF in high risk patients.
